|
2023 Conference Publication Impact of disease duration on predicting response to vedolizumab in patients with ulcerative colitis from the Vedolizumab Immunomodulator Enforced Withdrawal Study (VIEWS)Choi, R. C-H, Pudipeddi, A., Lin, H., Paramsothy, S., Ghaly, S., Begun, J., Kariyawasam, V., Yau, Y., Fung, C. and Leong, R. (2023). Impact of disease duration on predicting response to vedolizumab in patients with ulcerative colitis from the Vedolizumab Immunomodulator Enforced Withdrawal Study (VIEWS). HOBOKEN: WILEY. |
|
2023 Journal Article MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrierMcGuckin, Michael A., Davies, Julie M., Felgner, Pascal, Wong, Kuan Yau, Giri, Rabina, He, Yaowu, Moniruzzaman, Md., Kryza, Thomas, Sajiir, Haressh, Hooper, John D., Florin, Timothy H., Begun, Jakob, Oussalah, Abderrahim, Hasnain, Sumaira Z., Hensel, Michael and Sheng, Yong H. (2023). MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrier. Cellular and Molecular Gastroenterology and Hepatology, 16 (6), 985-1009. doi: 10.1016/j.jcmgh.2023.08.011 |
|
2023 Conference Publication Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experienceTan, W. L., Gilmore, R., Huang, A., Fernandes, R., An, Y-K and Begun, J. (2023). Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Variation of outcomes in inflammatory bowel disease at 10 Australian and New Zealand centers: Crohn's Colitis Cure data insights programMcnamara, J., Ghaly, S., Pipicella, J., Wilson, W., Goodfellow, T., Cheema, M., Lynch, K., Williams, A., Begun, J., Gearry, R., Kim, A., Haifer, C., Forbes, A., Lawrence, I., Schultz, M., Walker, G., Radford-Smith, G., Andrews, J. and Connor, S. (2023). Variation of outcomes in inflammatory bowel disease at 10 Australian and New Zealand centers: Crohn's Colitis Cure data insights program. HOBOKEN: WILEY. |
|
2023 Conference Publication The evolving role of technology in delivering consumer-centric care for inflammatory bowel disease: An Australasian experience with Crohn's Colitis Care's e-health consumer portalMcnamara, J., Pipicella, J., Ghaly, S., Gearry, R., Forbes, A., Begun, J., Wark, G., Lynch, K., Lawrence, I., Schultz, M., Walker, G., Radford-Smith, G., Brett, L., Verdon, C., Andrews, J. and Connor, S. (2023). The evolving role of technology in delivering consumer-centric care for inflammatory bowel disease: An Australasian experience with Crohn's Colitis Care's e-health consumer portal. HOBOKEN: WILEY. |
|
2023 Conference Publication Delayed flexible sigmoidoscopy remains a challenge in tertiary care of acute severe colitisRice, K., Fernandes, R., Hendy, P., Khoo, E., Walker, N., Howlett, M., An, Y-K and Begun, J. (2023). Delayed flexible sigmoidoscopy remains a challenge in tertiary care of acute severe colitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication From enemies to friends: Exploring the capacity of novel compounds secreted by "pathobiont" gut bacteria to attenuate inflammation in inflammatory bowel diseaseReed, H., Sehgal, A., Morrison, M. and Begun, J. (2023). From enemies to friends: Exploring the capacity of novel compounds secreted by "pathobiont" gut bacteria to attenuate inflammation in inflammatory bowel disease. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Cessation of corticosteroids after acute severe ulcerative colitis may be associated with increased colectomy risk: Results of the ANZ-ASUC study in collaboration with the ANZIBDCFernandes, R., Gilmore, R., Ruddick-Collins, L., Rice, K., Moore, G., Gazelakis, K., Vasudevan, A., Zhang, J., Wright, E., Schildkraut, T., Clark, N., Schultz, M., Brownson, A., Haifer, C., Bracken, L. M. L., Mahy, G., Swe, E., Judge, C., Ngoi, B., Lynch, K., Begun, J. and An, Y-K (2023). Cessation of corticosteroids after acute severe ulcerative colitis may be associated with increased colectomy risk: Results of the ANZ-ASUC study in collaboration with the ANZIBDC. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel diseaseTan, W. L., Barr, E., Pham, H., Fernandes, R., Khoo, E., An, Y-K and Begun, J. (2023). Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel disease. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case reportEtchegaray, A., Gilmore, R., An, Y-K and Begun, J. (2023). Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Patients from East Asia with acute severe ulcerative colitis have worse endoscopic severity but are more responsive to intravenous steroids than patients from Australasia: Preliminary results of the APAC-ASUC study in collaboration with the ANZIBDC and AOCCFernandes, R., Gilmore, R., Ruddick-Collins, L., Rice, K., Gazelakis, K., Moore, G., Vasudevan, A., Zhang, J., Wright, E., Schildkraut, T., Clark, N., Schultz, M., Brownson, A., Haifer, C., Bracken, L. M. L., Mahy, G., Swe, E., Lynch, K., Ngoi, B., Judge, C., Kim, D. H., Kim, H. S., Lee, H. S., Kim, K. O., Lee, Y. J., Kim, S-J, Lee, J., Song, E. M., Park, S. H. ... An, Y-K (2023). Patients from East Asia with acute severe ulcerative colitis have worse endoscopic severity but are more responsive to intravenous steroids than patients from Australasia: Preliminary results of the APAC-ASUC study in collaboration with the ANZIBDC and AOCC. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Upadacitinib improves endoscopic outcomes in patients with moderate to severely active Crohn's disease irrespective of previous failure to respond to biologics or conventional therapiesBegun, J., Feagan, B., Horst, S., Dryden, G., Lindsay, J., Ferrante, M., Dubcenco, E., Lacerda, A., Ford, S., Anyanwu, S., Zhou, Q., Liu, J., Chen, M. and Schreiber, S. (2023). Upadacitinib improves endoscopic outcomes in patients with moderate to severely active Crohn's disease irrespective of previous failure to respond to biologics or conventional therapies. HOBOKEN: WILEY. |
|
2023 Conference Publication Australian multicenter real-world experience of upadacitinib induction therapy for moderate to severe ulcerative colitisGilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugopal, K., Han, S., Bryant, R., Corte, C., Ding, J. N., An, Y-K and Begun, J. (2023). Australian multicenter real-world experience of upadacitinib induction therapy for moderate to severe ulcerative colitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Fistulizing Crohn's disease in a large real-world cohort: Crohn's Colitis Cure data insights programMcnamara, J., Wilson, W., Pipicella, J., Ghaly, S., Gearry, R., Forbes, A., Begun, J., Ng, W., Lynch, K., Lawrence, I., Schultz, M., Walker, G., Radford-Smith, G., Britt, L., Verdon, C., Andrews, J. and Connor, S. (2023). Fistulizing Crohn's disease in a large real-world cohort: Crohn's Colitis Cure data insights program. HOBOKEN: WILEY. |
|
2023 Journal Article Protocol for a single-arm feasibility study of photobiomodulation for fatigue, depression, and pain in inflammatory bowel diseaseEwais, Tatjana, Begun, Jakob and Laakso, E-Liisa (2023). Protocol for a single-arm feasibility study of photobiomodulation for fatigue, depression, and pain in inflammatory bowel disease. Biomedicines, 11 (8) 2179, 1-11. doi: 10.3390/biomedicines11082179 |
|
2023 Journal Article Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitisGilmore, Robert, Tan, Lian, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2023). Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis. Journal of Crohn's and Colitis, 17 (12), 2033-2036. doi: 10.1093/ecco-jcc/jjad115 |
|
2023 Conference Publication Goblet cell specific anti-apoptotic role of interleukin-24 in spondyloarthritis-associated ileitisCameron, A., Giri, R., Begun, J., Wells, T., Bergot, A. S. and Thomas, R. (2023). Goblet cell specific anti-apoptotic role of interleukin-24 in spondyloarthritis-associated ileitis. EULAR 2023 European Congress of Rheumatology, Milan, Italy, 31 May-3 June 2023. London, United Kingdom: BMJ Group. doi: 10.1136/annrheumdis-2023-eular.1346 |
|
2023 Journal Article Upadacitinib induction and maintenance therapy for Crohn's diseaseLoftus, Edward V., Panés, Julian, Lacerda, Ana P., Peyrin-Biroulet, Laurent, D'Haens, Geert, Panaccione, Remo, Reinisch, Walter, Louis, Edouard, Chen, Minhu, Nakase, Hiroshi, Begun, Jakob, Boland, Brigid S., Phillips, Charles, Mohamed, Mohamed-Eslam F, Liu, Jianzhong, Geng, Ziqian, Feng, Tian, Dubcenco, Elena and Colombel, Jean-Frederic (2023). Upadacitinib induction and maintenance therapy for Crohn's disease. The New England journal of medicine, 388 (21), 1966-1980. doi: 10.1056/NEJMoa2212728 |
|
2023 Conference Publication Post-Ustekinumab induction IL-12, IL-13 and Ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora studyAn, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Wong, Kam Fai, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Dr Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). Post-Ustekinumab induction IL-12, IL-13 and Ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora study. Digestive Disease Week DDW / AGA Conference 2023, Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(23)03564-3 |
|
2023 Conference Publication Baseline cytokine levels and microbiome signatures are associted with clinical response following ustekinumab induction in a multi-centre prospective cohort study of crohn's disease patients: results from the aurora studyAn, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Giri, Rabina, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). Baseline cytokine levels and microbiome signatures are associted with clinical response following ustekinumab induction in a multi-centre prospective cohort study of crohn's disease patients: results from the aurora study. Digestive Disease Week (DDW), Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/S0016-5085(23)02531-3 |
